GlobeImmune, Inc. Announces Presentation of Pre-Clinical Data on GI-10001 for Chronic Myelogenous Leukemia (CML) at International Conference on Molecular Targets and Cancer Therapeutics
October 25, 2007 06:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - October 25, 2007) - GlobeImmune, Inc. announced today results
from research on its GI-10001 Tarmogen® which is being investigated for
the treatment of drug...
GlobeImmune Raises $41.2 Million in Series C Financing
September 26, 2007 06:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - September 26, 2007) - GlobeImmune, Inc. today announced it has
raised $41.2 million through a Series C Preferred Stock financing. This
round was led by Wexford Capital...
GlobeImmune Updates Speaking Date and Time at the JPMorgan Healthcare Conference
January 05, 2007 12:23 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO -- (MARKET WIRE) -- January 5, 2007 -- GlobeImmune, Inc. announced today that
President and Chief Executive Officer Timothy C. Rodell, M.D. will present
at the JPMorgan Healthcare...
GlobeImmune CEO to Present at JPMorgan Healthcare Conference
January 03, 2007 12:36 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO -- (MARKET WIRE) -- January 3, 2007 -- GlobeImmune, Inc. announced today that
President and Chief Executive Officer, Timothy C. Rodell, M.D., will
present at the JPMorgan Healthcare...
GlobeImmune Announces Presentation of Positive Interim Results From a Study of the GI-5005 Tarmogen in Patients With Chronic Hepatitis C Infection
October 30, 2006 08:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO -- (MARKET WIRE) -- October 30, 2006 -- GlobeImmune, Inc. today announced positive
interim results from Study GI-5005-01, a randomized, placebo-controlled,
multi-center,...
GlobeImmune Announces GI-5005 Tarmogen Data for Chronic Hepatitis C Infection to Be Presented at the American Association for the Study of Liver Diseases (AASLD)
October 17, 2006 12:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO -- (MARKET WIRE) -- October 17, 2006 -- GlobeImmune, Inc. announced today that the
interim results from a placebo-controlled Phase 1b study of GI-5005 in
patients chronically infected...